12: Dako brings BioPorto’s kidney injury test to the world market
November 23 2010
Announcement no. 12
Dako brings BioPorto’s kidney injury test to the world market
From January 2011, Dako will be distributing The NGAL Test – BioPorto’s new test for measuring acute kidney injury.
"Dako is the perfect partner for us," says Thea Olesen, CEO of BioPorto. "Dako sells its products in more than 80 countries and they have decades of experience in the launch and sale of diagnostic tests. In addition to ensuring The NGAL Test a quick and direct access to most of the world market, the contract with Dako will also contribute significantly to securing the right level of technical support that is invaluable when launching a completely new type of test. "
Dako is also pleased with the agreement: "The diagnosis of kidney disease is already one of Dako's core areas in the Reagent Partnership Division, and with access to The NGAL Test we will now get an opportunity to offer our customers a popular new product, which both we and our customers look forward to "says Christina Lindved Turner, Vice President of Reagent Partnership Division at Dako.
The agreement does not prevent BioPorto from optimizing sales channels for The NGAL Test. BioPorto is therefore continuing the discussion on cooperation with the global diagnostics companies that are interested in marketing the kidney injury marker as an important product in the portfolio of tests for their own analytical instruments.
